Brief: Inmagene Successfully Doses First Patient In Adaptive Trial Of IMG-007
01/07/2025 22:37
July 1 (Reuters) - Ikena Oncology Inc IKNA.O: IKENA ONCOLOGY INC - INMAGENE SUCCESSFULLY DOSES FIRST PATIENT IN ADAPTIVE TRIAL OF IMG-007 - SEC FILING IKENA ONCOLOGY INC: INMAGENE EXPECTS TOPLINE DATA IN Q4 2026 Further company coverage: IKNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImageneBio
See all newsU.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Brief: ImageneBio Inc - On Oct 23, Elects Not To Renew Agreement With Miragene - SEC Filing
ImageneBio Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals